NATCO Pharma Limited (NATCOPHARM.BO)
INR 1475.25
(2.03%)
INR 1475.25
(2.03%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 53 Million INR | 381.82% |
| 2022 | 11 Million INR | -86.25% |
| 2021 | 80 Million INR | 788.89% |
| 2020 | 9 Million INR | 0.0% |
| 2019 | 9 Million INR | 212.5% |
| 2018 | -8 Million INR | 0.0% |
| 2017 | -8 Million INR | 0.0% |
| 2016 | -8 Million INR | 0.0% |
| 2015 | -8 Million INR | -100.82% |
| 2014 | 970 Million INR | 1.59% |
| 2013 | 954.86 Million INR | -30.72% |
| 2012 | 1.37 Billion INR | 2.78% |
| 2011 | 1.34 Billion INR | 6.91% |
| 2010 | 1.25 Billion INR | 4.96% |
| 2009 | 1.19 Billion INR | -5.3% |
| 2008 | 1.26 Billion INR | 34.06% |
| 2007 | 941.33 Million INR | 23.15% |
| 2006 | 764.36 Million INR | -4.52% |
| 2005 | 800.52 Million INR | -28.03% |
| 2004 | 1.11 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2023 FY | 53 Million INR | 381.82% |
| 2023 Q4 | 53 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 62 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 11 Million INR | 0.0% |
| 2022 FY | 11 Million INR | -86.25% |
| 2022 Q2 | 9 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 80 Million INR | 788.89% |
| 2021 Q2 | 94 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 80 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 9 Million INR | 0.0% |
| 2020 FY | 9 Million INR | 0.0% |
| 2020 Q2 | 9 Million INR | 0.0% |
| 2019 FY | 9 Million INR | 212.5% |
| 2019 Q2 | - INR | 0.0% |
| 2019 Q3 | - INR | 0.0% |
| 2019 Q4 | 9 Million INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2018 FY | -8 Million INR | 0.0% |
| 2018 Q3 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2017 Q3 | - INR | 0.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 FY | -8 Million INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q3 | - INR | 0.0% |
| 2016 FY | -8 Million INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2015 Q2 | 35.9 Million INR | 0.0% |
| 2015 FY | -8 Million INR | -100.82% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | - INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q2 | 771.3 Million INR | 0.0% |
| 2014 FY | 970 Million INR | 1.59% |
| 2014 Q4 | 970 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 954.86 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 954.86 Million INR | -30.72% |
| 2013 Q2 | 1.31 Billion INR | 0.0% |
| 2012 Q4 | 1.37 Billion INR | 0.0% |
| 2012 FY | 1.37 Billion INR | 2.78% |
| 2012 Q2 | 1.38 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 1.34 Billion INR | 0.0% |
| 2011 FY | 1.34 Billion INR | 6.91% |
| 2010 FY | 1.25 Billion INR | 4.96% |
| 2009 FY | 1.19 Billion INR | -5.3% |
| 2008 FY | 1.26 Billion INR | 34.06% |
| 2007 FY | 941.33 Million INR | 23.15% |
| 2006 FY | 764.36 Million INR | -4.52% |
| 2005 FY | 800.52 Million INR | -28.03% |
| 2004 FY | 1.11 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 235.2 Million INR | 77.466% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -279.439% |
| Sigachi Industries Limited | 265.79 Million INR | 80.06% |
| Bal Pharma Limited | 363.82 Million INR | 85.433% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 52.52% |
| Medico Remedies Limited | 8.67 Million INR | -511.162% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Venus Remedies Limited | 386.8 Million INR | 86.298% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 50.281% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 96.223% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.054% |
| Aarti Drugs Limited | 2.75 Billion INR | 98.075% |
| Lupin Limited | 1.55 Billion INR | 96.587% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.752% |
| Zydus Lifesciences Limited | 251 Million INR | 78.884% |
| Windlas Biotech Limited | 20.18 Million INR | -162.636% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.19% |
| Valiant Laboratories Limited | 746.63 Million INR | 92.901% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 77.58% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 94.992% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.087% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 85.109% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -298.496% |
| Bajaj HealthCare Limited | 650.34 Million INR | 91.85% |
| RPG Life Sciences Limited | -30.3 Million INR | 274.917% |
| Mankind Pharma Limited | 248.67 Million INR | 78.687% |
| Laurus Labs Limited | 8.6 Billion INR | 99.384% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.787% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 4447.826% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.67% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 91.571% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 96.506% |
| Unichem Laboratories Limited | 382.22 Million INR | 86.134% |
| Sequent Scientific Limited | 1.42 Billion INR | 96.286% |
| Novartis India Limited | 50.7 Million INR | -4.536% |
| Wanbury Limited | 820 Million INR | 93.537% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 75.042% |
| Wockhardt Limited | 8.91 Billion INR | 99.405% |
| Themis Medicare Limited | 267.74 Million INR | 80.205% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 29.866% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.833% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 64.095% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.115% |
| Divi's Laboratories Limited | 20 Million INR | -165.0% |
| Gufic Biosciences Limited | 1.53 Billion INR | 96.558% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.475% |
| Procter & Gamble Health Limited | 68.8 Million INR | 22.965% |
| FDC Limited | 2.46 Million INR | -2049.23% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 97.112% |
| Granules India Limited | 689.71 Million INR | 92.316% |
| Medicamen Biotech Limited | 12.55 Million INR | -322.143% |
| Alkem Laboratories Limited | 400 Million INR | 86.75% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -90.401% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -1386.676% |
| Megasoft Limited | 1.35 Billion INR | 96.095% |
| ZIM Laboratories Limited | 356 Million INR | 85.113% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.211% |
| Neuland Laboratories Limited | 449.2 Million INR | 88.201% |
| Morepen Laboratories Limited | 33.64 Million INR | -57.551% |
| Hikal Limited | 4.22 Billion INR | 98.747% |
| Indoco Remedies Limited | 3.51 Billion INR | 98.493% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -13150.0% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 60.312% |
| Hester Biosciences Limited | 1.81 Billion INR | 97.084% |